Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Tumour Cell Anaplasia and Multinucleation as Prognosticators in Oropharyngeal Squamous Cell Carcinoma.

Molony P, Werner R, Martin C, Callanan D, Sheahan P, Heffron C, Feeley L.

Head Neck Pathol. 2019 Sep 24. doi: 10.1007/s12105-019-01081-7. [Epub ahead of print]

PMID:
31552619
2.

MUST Beg to Differ.

Albini T, Callaway NF, Jaffe GJ, Feuer W, Davis J, Goldstein D, Lowder C, Lin P, Nguyen Q, Srivastava S, Callanan D, Galor A, Goldhardt R, Flynn H Jr.

Ophthalmic Surg Lasers Imaging Retina. 2019 May 1;50(5):266-268. doi: 10.3928/23258160-20190503-01.

PMID:
31100155
3.

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.

Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, Cheetham JK, Hohman TC, Kim K, López FJ, Schneider S.

J Ocul Pharmacol Ther. 2018 Nov 9. doi: 10.1089/jop.2018.0062. [Epub ahead of print]

4.

Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.

Heissigerová J, Callanan D, de Smet MD, Srivastava SK, Karkanová M, Garcia-Garcia O, Kadayifcilar S, Ozyazgan Y, Vitti R, Erickson K, Athanikar A, Chu K, Saroj N, Sundaram PA, Varona R, Corp-Dit-Genti V, Buggage R, Cheng Y, Soo Y, Nguyen QD.

Ophthalmology. 2019 Mar;126(3):428-437. doi: 10.1016/j.ophtha.2018.09.044. Epub 2018 Oct 11.

PMID:
30316888
5.

Evaluation of an Interprofessional Oral Health Assessment Activity in Advanced Practice Nursing Education.

Estes KR, Callanan D, Rai N, Plunkett K, Brunson D, Tiwari T.

J Dent Educ. 2018 Oct;82(10):1084-1090. doi: 10.21815/JDE.018.103.

6.

Potentiating Response to Drop-Jump Protocols on Sprint Acceleration: Drop-Jump Volume and Intrarepetition Recovery Duration.

Byrne PJ, Moody JA, Cooper SM, Callanan D, Kinsella S.

J Strength Cond Res. 2018 Jul 2. doi: 10.1519/JSC.0000000000002720. [Epub ahead of print]

PMID:
29979275
7.

Outcomes of transoral laser microsurgery for oropharyngeal squamous cell carcinoma in Ireland and review of the literature on transoral approaches.

Woods RSR, Geyer L, Ionescu A, Callanan D, Sheahan P.

Ir J Med Sci. 2019 May;188(2):397-403. doi: 10.1007/s11845-018-1842-x. Epub 2018 Jun 21. Review.

PMID:
29926338
8.

When a Child Dies Unexpectedly: No Truth Be Told.

Callanan DL, McClain WD.

Am J Forensic Med Pathol. 2018 Sep;39(3):276-278. doi: 10.1097/PAF.0000000000000384.

PMID:
29659376
9.

Urinary perforation in spina bifida: Neurosurgical and infectious consequences.

Callanan D, Phillips T, Tullous M.

SAGE Open Med Case Rep. 2017 Dec 11;5:2050313X17744986. doi: 10.1177/2050313X17744986. eCollection 2017.

10.

Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.

Regillo CD, Callanan DG, Do DV, Fine HF, Holekamp NM, Kuppermann BD, Singer MA, Singh RP.

Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):291-301. doi: 10.3928/23258160-20170329-03.

PMID:
28419394
11.

Rate of Retinal Detachment after Early Prophylactic Vitrectomy for Acute Retinal Necrosis.

Huang JM, Callanan P, Callanan D, Wang RC.

Ocul Immunol Inflamm. 2018;26(2):204-207. doi: 10.1080/09273948.2016.1202986. Epub 2016 Aug 11.

PMID:
27715365
12.

Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.

Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, Do DV; READ-3 Study Group.

Ophthalmology. 2016 Dec;123(12):2581-2587. doi: 10.1016/j.ophtha.2016.08.040. Epub 2016 Oct 1.

PMID:
27707550
13.

A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Callanan DG, Loewenstein A, Patel SS, Massin P, Corcóstegui B, Li XY, Jiao J, Hashad Y, Whitcup SM.

Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):463-473. doi: 10.1007/s00417-016-3472-1. Epub 2016 Sep 8.

PMID:
27632215
14.

NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.

Williams PD, Chong D, Fuller T, Callanan D.

Retina. 2016 May;36(5):909-13. doi: 10.1097/IAE.0000000000000801.

PMID:
27115856
15.

Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).

Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus DM, Halperin L, Sadiq MA, Rajagopalan N, Campochiaro PA, Nguyen QD; READ-3 Study Group.

Eye (Lond). 2015 Dec;29(12):1538-44. doi: 10.1038/eye.2015.142. Epub 2015 Jul 31.

16.

Spontaneous dislocation of fluocinolone acetonide implant pellets from their suture struts.

Itty S, Callanan D, Jones R, Pecen P, Martel J, Jaffe GJ.

Am J Ophthalmol. 2015 May;159(5):868-76.e1. doi: 10.1016/j.ajo.2015.01.031. Epub 2015 Jan 30.

PMID:
25640410
17.

All that wheezes: A young infant with a mediastinal mass.

Callanan DL, Tong T, Doski JJ.

SAGE Open Med Case Rep. 2014 Oct 9;2:2050313X14553864. doi: 10.1177/2050313X14553864. eCollection 2014.

18.

Stepping outside the box: an adolescent with a new-onset seizure.

Howell CM, Davis MS, Callanan DL.

Pediatr Emerg Care. 2013 Sep;29(9):1011-2. doi: 10.1097/PEC.0b013e3182a32065.

PMID:
24201984
19.

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group.

Ophthalmology. 2013 Sep;120(9):1843-51. doi: 10.1016/j.ophtha.2013.02.018. Epub 2013 May 22.

PMID:
23706947
20.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJT, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group.

Ophthalmology. 2013 Mar;120(3):593-599. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.

21.

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.

Williams PD, Callanan D, Solley W, Avery RL, Pieramici DJ, Aaberg T.

Clin Ophthalmol. 2012;6:1519-25. doi: 10.2147/OPTH.S31010. Epub 2012 Sep 17.

22.

Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial.

Stalmans I, Callanan DG, Dirks MS, Moster MR, Robin AL, Van Calster J, Scheib SA, Dickerson JE Jr, Landry TA, Bergamini MV.

J Ocul Pharmacol Ther. 2012 Dec;28(6):559-65. doi: 10.1089/jop.2012.0063. Epub 2012 Aug 3.

23.

Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis.

Kurup SK, Oliver A, Emanuelli A, Hau V, Callanan D.

Retina. 2012 Nov-Dec;32(10):2096-101. doi: 10.1097/IAE.0b013e31825dd281.

PMID:
22718154
24.

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.

Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B, Mann ES, Eliott D.

Ophthalmology. 2011 Aug;118(8):1580-7. doi: 10.1016/j.ophtha.2011.02.048.

PMID:
21813090
25.

Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.

Rush RB, Goldstein DA, Callanan DG, Meghpara B, Feuer WJ, Davis JL.

Am J Ophthalmol. 2011 Apr;151(4):630-6. doi: 10.1016/j.ajo.2010.10.005. Epub 2011 Feb 1.

26.

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F.

Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.

27.

Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection.

Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG.

Retina. 2010 Oct;30(9):1432-40. doi: 10.1097/IAE.0b013e3181dc04da.

PMID:
20559156
28.

Long term gastroesophageal reflux after atrial fibrillation ablation.

Callanan D.

Heart Rhythm. 2010 Mar;7(3):e1; author reply e1-2. doi: 10.1016/j.hrthm.2009.12.021. Epub 2010 Jan 4. No abstract available.

PMID:
20122879
29.

Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.

Birch DG, Williams PD, Callanan D, Wang R, Locke KG, Hood DC.

Retina. 2010 Jun;30(6):930-7. doi: 10.1097/IAE.0b013e3181c720b4.

30.

Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema.

Chew EY, Kim J, Coleman HR, Aiello LP, Fish G, Ip M, Haller JA, Figueroa M, Martin D, Callanan D, Avery R, Hammel K, Thompson DJ, Ferris FL 3rd.

Retina. 2010 Mar;30(3):459-67. doi: 10.1097/IAE.0b013e3181bcf1a0.

31.

Diagnosis of systemic metastatic retinal lymphoma.

Cao X, Shen D, Callanan DG, Mochizuki M, Chan CC.

Acta Ophthalmol. 2011 Mar;89(2):e149-54. doi: 10.1111/j.1755-3768.2009.01797.x.

32.

Vitreous metastases of primary cutaneous B-cell lymphoma.

Chong DY, Johnson MW, Shen D, Chan CC, Callanan DG.

Ocul Immunol Inflamm. 2009 Sep-Oct;17(5):342-4. doi: 10.3109/09273940903144705.

33.

The role of difluprednate ophthalmic emulsion in clinical practice.

Jamal KN, Callanan DG.

Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29.

34.

Topical nepafenac in the treatment of diabetic macular edema.

Callanan D, Williams P.

Clin Ophthalmol. 2008 Dec;2(4):689-92.

35.

Pituitary adenoma presenting as bilateral bullous exudative retinal detachments: a clinicopathologic report.

Williams P, Chan CC, Buggage R, Srivastava S, Callanan D.

Retin Cases Brief Rep. 2009 Spring;3(2):230-2. doi: 10.1097/ICB.0b013e31815f3cac.

PMID:
25391084
36.

Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma.

Robin AL, Suan EP, Sjaarda RN, Callanan DG, Defaller J; Alcon Anecortave Acetate for IOP Research Team.

Arch Ophthalmol. 2009 Feb;127(2):173-8. doi: 10.1001/archophthalmol.2008.595.

PMID:
19204235
37.

Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy.

Dyer D, Callanan D, Bochow T, Abraham P, Lambert HM, Lee SY, Schneiderman T, Potts SL, Walker TM.

Retina. 2009 Jan;29(1):38-45. doi: 10.1097/IAE.0b013e318188c6e2.

PMID:
18827733
38.

Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema.

Hariprasad SM, Callanan D.

Retin Cases Brief Rep. 2008 Fall;2(4):304-8. doi: 10.1097/ICB.0b013e31809ed9db.

PMID:
25390598
39.

Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.

Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL.

Arch Ophthalmol. 2008 Sep;126(9):1191-201. doi: 10.1001/archopht.126.9.1191.

PMID:
18779477
40.

Celiac disease presenting as a xerophthalmic fundus.

Witherspoon SR, Callanan D.

Retina. 2008 Mar;28(3):525-6. doi: 10.1097/IAE.0b013e31816079d6. No abstract available.

PMID:
18327150
41.

Cystoid and diabetic macular edema treated with nepafenac 0.1%.

Hariprasad SM, Callanan D, Gainey S, He YG, Warren K.

J Ocul Pharmacol Ther. 2007 Dec;23(6):585-90.

PMID:
18001248
42.

Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.

Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL.

Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8.

PMID:
17923537
43.

Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema.

Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, Davis MD, Feman SS, Ferris F, Friedman SM, Garcia CA, Glassman AR, Han DP, Le D, Kollman C, Lauer AK, Recchia FM, Solomon SD.

Arch Ophthalmol. 2007 Apr;125(4):469-80.

44.

Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion.

Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT.

Retina. 2006 Oct;Suppl:1-16.

PMID:
17050954
45.

Early onset endophthalmitis caused by Aspergillus species following cataract surgery.

Callanan D, Scott IU, Murray TG, Oxford KW, Bowman CB, Flynn HW Jr.

Am J Ophthalmol. 2006 Sep;142(3):509-11.

PMID:
16935607
46.

Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.

Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group.

Ophthalmology. 2006 Jun;113(6):1020-7. Epub 2006 May 9.

PMID:
16690128
47.

The white dot syndromes.

Quillen DA, Davis JB, Gottlieb JL, Blodi BA, Callanan DG, Chang TS, Equi RA.

Am J Ophthalmol. 2004 Mar;137(3):538-50. Review.

PMID:
15013878
49.

Propionibacterium acnes endophthalmitis diagnosed by microdissection and PCR.

Buggage RR, Callanan DG, Shen DF, Chan CC.

Br J Ophthalmol. 2003 Sep;87(9):1190-1. No abstract available. Erratum in: Br J Ophthalmol. 2003 Nov;87(11):1432.

50.

Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome.

Busquets MA, Shah GK, Wickens J, Callanan D, Blinder KJ, Burgess D, Grand MG, Holekamp NM, Boniuk I, Joseph DP, Thomas MA, Fish E, Bakal J, Hollands H, Sharma S.

Retina. 2003 Jun;23(3):299-306.

PMID:
12824828

Supplemental Content

Loading ...
Support Center